These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 17360108

  • 1. An activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR.
    Hou G, Xue L, Lu Z, Fan T, Tian F, Xue Y.
    Cancer Lett; 2007 Aug 18; 253(2):236-48. PubMed ID: 17360108
    [Abstract] [Full Text] [Related]

  • 2. [Effects of mTOR siRNA on mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cells and the growth of transplanted tumor in nude mice].
    Liu MY, Hou GQ, Zhang Y, Bei WJ, Yan AH.
    Zhonghua Zhong Liu Za Zhi; 2011 May 18; 33(5):334-9. PubMed ID: 21875460
    [Abstract] [Full Text] [Related]

  • 3. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
    Amornphimoltham P, Patel V, Sodhi A, Nikitakis NG, Sauk JJ, Sausville EA, Molinolo AA, Gutkind JS.
    Cancer Res; 2005 Nov 01; 65(21):9953-61. PubMed ID: 16267020
    [Abstract] [Full Text] [Related]

  • 4. Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas.
    Lin F, Zhang PL, Yang XJ, Prichard JW, Lun M, Brown RE.
    Ann Clin Lab Sci; 2006 Nov 01; 36(3):283-93. PubMed ID: 16951269
    [Abstract] [Full Text] [Related]

  • 5. Morphoproteomic and pharmacoproteomic rationale for mTOR effectors as therapeutic targets in head and neck squamous cell carcinoma.
    Brown RE, Zhang PL, Lun M, Zhu S, Pellitteri PK, Riefkohl W, Law A, Wood GC, Kennedy TL.
    Ann Clin Lab Sci; 2006 Nov 01; 36(3):273-82. PubMed ID: 16951268
    [Abstract] [Full Text] [Related]

  • 6. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy.
    Hidalgo M, Rowinsky EK.
    Oncogene; 2000 Dec 27; 19(56):6680-6. PubMed ID: 11426655
    [Abstract] [Full Text] [Related]

  • 7. The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells.
    Grozinsky-Glasberg S, Rubinfeld H, Nordenberg Y, Gorshtein A, Praiss M, Kendler E, Feinmesser R, Grossman AB, Shimon I.
    Mol Cell Endocrinol; 2010 Feb 05; 315(1-2):87-94. PubMed ID: 19815051
    [Abstract] [Full Text] [Related]

  • 8. Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.
    Gibbons JJ, Abraham RT, Yu K.
    Semin Oncol; 2009 Dec 05; 36 Suppl 3():S3-S17. PubMed ID: 19963098
    [Abstract] [Full Text] [Related]

  • 9. Downregulation of p70S6K Enhances Cell Sensitivity to Rapamycin in Esophageal Squamous Cell Carcinoma.
    Lu Z, Peng K, Wang N, Liu HM, Hou G.
    J Immunol Res; 2016 Dec 05; 2016():7828916. PubMed ID: 27595116
    [Abstract] [Full Text] [Related]

  • 10. RAD001 offers a therapeutic intervention through inhibition of mTOR as a potential strategy for esophageal cancer.
    Wang ZG, Fukazawa T, Nishikawa T, Watanabe N, Sakurama K, Motoki T, Hatakeyama S, Omori O, Ohara T, Tanabe S, Fujiwara Y, Takaoka M, Shirakawa Y, Yamatsuji T, Tanaka N, Naomoto Y.
    Oncol Rep; 2010 Apr 05; 23(4):1167-72. PubMed ID: 20204306
    [Abstract] [Full Text] [Related]

  • 11. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
    Gorshtein A, Rubinfeld H, Kendler E, Theodoropoulou M, Cerovac V, Stalla GK, Cohen ZR, Hadani M, Shimon I.
    Endocr Relat Cancer; 2009 Sep 05; 16(3):1017-27. PubMed ID: 19509067
    [Abstract] [Full Text] [Related]

  • 12. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors.
    Kenerson HL, Aicher LD, True LD, Yeung RS.
    Cancer Res; 2002 Oct 15; 62(20):5645-50. PubMed ID: 12384518
    [Abstract] [Full Text] [Related]

  • 13. mTOR and P70 S6 kinase expression in primary liver neoplasms.
    Sahin F, Kannangai R, Adegbola O, Wang J, Su G, Torbenson M.
    Clin Cancer Res; 2004 Dec 15; 10(24):8421-5. PubMed ID: 15623621
    [Abstract] [Full Text] [Related]

  • 14. Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line.
    Grozinsky-Glasberg S, Franchi G, Teng M, Leontiou CA, Ribeiro de Oliveira A, Dalino P, Salahuddin N, Korbonits M, Grossman AB.
    Neuroendocrinology; 2008 Dec 15; 87(3):168-81. PubMed ID: 18025810
    [Abstract] [Full Text] [Related]

  • 15. Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death.
    Ronellenfitsch MW, Brucker DP, Burger MC, Wolking S, Tritschler F, Rieger J, Wick W, Weller M, Steinbach JP.
    Brain; 2009 Jun 15; 132(Pt 6):1509-22. PubMed ID: 19416948
    [Abstract] [Full Text] [Related]

  • 16. Mammalian target of rapamycin is required for thrombopoietin-induced proliferation of megakaryocyte progenitors.
    Drayer AL, Olthof SG, Vellenga E.
    Stem Cells; 2006 Jan 15; 24(1):105-14. PubMed ID: 16123382
    [Abstract] [Full Text] [Related]

  • 17. Expression and activity of mTOR and its substrates in different cell cycle phases and in oral squamous cell carcinomas of different malignant grade.
    Liu Y, Hidayat S, Su WH, Deng X, Yu DH, Yu BZ.
    Cell Biochem Funct; 2007 Jan 15; 25(1):45-53. PubMed ID: 16927414
    [Abstract] [Full Text] [Related]

  • 18. Phosphorylated p70S6K expression is an independent prognosticator for patients with esophageal squamous cell carcinoma.
    Li SH, Chen CH, Lu HI, Huang WT, Tien WY, Lan YC, Lee CC, Chen YH, Huang HY, Chang AY, Lin WC.
    Surgery; 2015 Mar 15; 157(3):570-80. PubMed ID: 25726316
    [Abstract] [Full Text] [Related]

  • 19. Insulin-like growth factor-1 (IGF-1) and leucine activate pig myogenic satellite cells through mammalian target of rapamycin (mTOR) pathway.
    Han B, Tong J, Zhu MJ, Ma C, Du M.
    Mol Reprod Dev; 2008 May 15; 75(5):810-7. PubMed ID: 18033679
    [Abstract] [Full Text] [Related]

  • 20. Sirolimus inhibits human pancreatic carcinoma cell proliferation by a mechanism linked to the targeting of mTOR/HIF-1 alpha/VEGF signaling.
    Wang Y, Zhao Q, Ma S, Yang F, Gong Y, Ke C.
    IUBMB Life; 2007 Nov 15; 59(11):717-21. PubMed ID: 17968710
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.